Navigating international differences in regulations for cellular starting material is complex. This is particularly true because the rapid advancement of the industry sometimes precedes regulatory guidance.

When you’re procuring cellular starting material or distributing a cell or gene therapy product across international borders, you must consider the country or regional requirements at play and where they diverge.

This on-demand webinar offers insights into the common challenges allogeneic cell and gene therapy sponsors face when treating a global patient population with therapies using healthy donor starting material.


Beth Kuker
Manager, Regulatory Affairs
NMDP BioTherapies

Petr Machalik
International Collection Network Manager,
NMDP BioTherapies

Nicole Prokopishyn
Director, Cellular Therapy Lab
Alberta Precision Laboratories

Salmah Ahmed
Director, Quality and Regulation
Anthony Nolan

View Webinar